ArticleFrontiers in pharmacology2022
Echinacoside Inhibits Osteoclast Function by Down-Regulating PI3K/Akt/C-Fos to Alleviate Osteolysis Caused by Periprosthetic Joint Infection.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Effects of intra-articular injection of dimethyl itaconate combined with systemic vancomycin on periprosthetic joint infection in rats.Bone & joint research · 2026Article
- GPX7 Accelerates epithelial-mesenchymal Transition and Drives HCC Progression Via PI3K/AKT Signaling Pathway.Cell biochemistry and biophysics · 2026Article
- Phenylethanoid Glycosides fromNutrients · 2026Review
- Echinacoside Improves Memory Function and Bone Mineral Density in the Aged SAMP8 Mouse Model.Molecular neurobiology · 2025Article
- LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis.PloS one · 2025Article
- γ-Mangostin attenuates osteoclastogenesis and bone resorption by suppressing the PI3K/AKT/NF-κB pathway.Frontiers in pharmacology · 2025Article
- Identification of immune infiltration and immune-related biomarkers of periprosthetic joint infection.Heliyon · 2024Article
- The Role of Herbal Medicine in Modulating Bone Homeostasis.Current topics in medicinal chemistry · 2024Review
- Echinacoside Induces UCP1- and ATP-Dependent Thermogenesis in Beige AdipocytesJournal of microbiology and biotechnology · 2023Article
- The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson's disease.Cell death discovery · 2023Article
- The Potential of Natural Compounds Regulating Autophagy in the Treatment of Osteoporosis.Journal of inflammation research · 2023Review
- Unraveling the potential mechanisms of the anti-osteoporotic effects of theFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infected osteolysis as a common secondary osteoporosis is associated with excessive osteoclastogenesis and bone resorption. The inhibition of osteoclastogenesis and bone resorption have been demonstrated an effective approach in the treatment of osteolytic diseases. Echinacoside (ECH) is a natural phenylethanoid glycoside with multiple biological functions, including anti-inflammatory, antioxidant, and osteoblast differentiation promotion. However, the effects of ECH on osteoclast differentiation and bone resorption function remain unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.